FRX Stock Overview
Operates as a biopharmaceutical company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Fennec Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.65 |
| 52 Week High | US$15.43 |
| 52 Week Low | US$5.65 |
| Beta | 0.27 |
| 11 Month Change | -12.40% |
| 3 Month Change | -25.66% |
| 1 Year Change | -50.00% |
| 33 Year Change | -53.99% |
| 5 Year Change | -29.20% |
| Change since IPO | -98.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| FRX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -4.1% | -13.2% | -0.7% |
| 1Y | -50.0% | -8.5% | 20.2% |
Return vs Industry: FRX underperformed the Canadian Biotechs industry which returned -8.5% over the past year.
Return vs Market: FRX underperformed the Canadian Market which returned 20.2% over the past year.
Price Volatility
| FRX volatility | |
|---|---|
| FRX Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: FRX has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: FRX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 29 | Rosty Raykov | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. Fundamentals Summary
| FRX fundamental statistics | |
|---|---|
| Market cap | CA$154.21m |
| Earnings (TTM) | -CA$1.60m |
| Revenue (TTM) | CA$69.53m |
2.2x
P/S Ratio-96.6x
P/E RatioIs FRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRX income statement (TTM) | |
|---|---|
| Revenue | US$49.35m |
| Cost of Revenue | US$3.20m |
| Gross Profit | US$46.15m |
| Other Expenses | US$47.28m |
| Earnings | -US$1.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 93.52% |
| Net Profit Margin | -2.30% |
| Debt/Equity Ratio | -620.7% |
How did FRX perform over the long term?
See historical performance and comparison